conatumumab

{
  "id": "MLC-T-ONC-012716",
  "term": "conatumumab",
  "field": "Oncology and biomedicine",
  "definition": "A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.",
  "synonyms": [
    "anti-TRAIL receptor 2 monoclonal antibody AMG 655",
    "immunoglobulin G1, anti-(human tumor necrosis factor receptor superfamily member 10b (death receptor 5, trail-R2, CD262 antigen))",
    "monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))gamma-1 heavy chain (225-215')-disulphide with kappa light chain (231-231'':234-234'')-bisdisulphide dimer"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/conatumumab/"
}